<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126880</url>
  </required_header>
  <id_info>
    <org_study_id>AVX-201</org_study_id>
    <nct_id>NCT00126880</nct_id>
  </id_info>
  <brief_title>AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV</brief_title>
  <official_title>A Phase II, Randomised, Double-blind, Dose-ranging Study of AVX754 Versus Lamivudine in Treatment-experienced HIV-1 Infected Patients With the M184V Mutation in Reverse Transcriptase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avexa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avexa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will measure how safe and effective AVX754 (a new drug for the treatment of HIV) is
      in treating HIV-1 infected people who have failed treatment with lamivudine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lamivudine or emtricitabine are commonly used in combination with other drugs for first-line
      treatment of HIV infection. Although effective initially, many people later on develop
      resistance to some or all of the drugs (including lamivudine) leading to virological failure.
      Resistance is associated with characteristic mutations, which for lamivudine is the M184V
      mutation. A change to new, active drugs must take place when patients fail their current
      regime, to regain control of the virus. Although there are other types of drugs available for
      second line treatment, there is currently no fully active, well tolerated cytidine analogue
      that can replace lamivudine in a second-line regimen when patients fail first line treatment.
      This study will measure the efficacy and safety of AVX754 (a novel cytidine analogue with
      activity against HIV resistant to other nucleosides) as part of a new regimen to treat
      patients who have failed treatment containing lamivudine, compared to the best alternative
      new regimen which continues to include lamivudine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HIV RNA levels at day 21</measure>
    <time_frame>day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-weighted average change from baseline in HIV RNA levels through 21 days</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HIV RNA levels at days 7, 14, 21</measure>
    <time_frame>days 7, 14, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with HIV RNA levels &lt;400 or &lt;50 at days 7, 14, 21, and weeks 24 and 48</measure>
    <time_frame>days 7, 14, 21, and weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline and change in ratio of CD4+ and CD8+ cells at day 21 and weeks 24 and 48</measure>
    <time_frame>day 21 and weeks 24 and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>600mg BID ATC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg BID ATC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800mg BID ATC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg BID ATC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150mg BID 3TC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150mg BID 3TC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVX754</intervention_name>
    <description>apricitabine, 600mg BID or 800mg BID</description>
    <arm_group_label>600mg BID ATC</arm_group_label>
    <arm_group_label>800mg BID ATC</arm_group_label>
    <other_name>apricitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3TC</intervention_name>
    <description>3TC, 150mg BID</description>
    <arm_group_label>150mg BID 3TC</arm_group_label>
    <other_name>lamivudine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected

          -  M184V mutation in reverse transcriptase

          -  Currently taking lamivudine

          -  Viral load &gt;2000 copies/ml

        Exclusion Criteria:

          -  Hepatitis B surface antigen positive

          -  Pregnant or breastfeeding females

          -  Hepatitis C RNA positive and requiring treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan W Cox, Ph D</last_name>
    <role>Study Director</role>
    <affiliation>Avexa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avexa (co-ordinating sites in Australia and Argentina)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2005</study_first_submitted>
  <study_first_submitted_qc>August 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2005</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Susan Cox</name_title>
    <organization>Avexa</organization>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>anti-retroviral therapy</keyword>
  <keyword>nucleoside analogue</keyword>
  <keyword>reverse transcriptase</keyword>
  <keyword>lamivudine</keyword>
  <keyword>resistance mutation</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

